RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Nanophore ATP

Product
Developers: Synthol
Date of the premiere of the system: June 2023
Branches: Pharmaceuticals, Medicine, Healthcare

2023: Product Announcement

The Institute of Analytical Instrumentation of the Russian Academy of Sciences, together with the research and production company "," Synthol has completed the development of a domestic sequencer for mass parallel sequencing. DNA The device is called "Nanophore SPS," works on the principle of sequencing by synthesis on a domestic reagent compatible with reagents. Illumina This was reported in "Sintol" at the end of June 2023.

A device such as a sequencer allows next-generation sequencing, or NGS. This technique is necessary for genomic analysis. The data obtained are used to diagnose rare hereditary diseases, as well as many pathologies in such areas of medicine as neurology, cardiology, ophthalmology, psychiatry, epileptology, nephrology, etc. In addition, the genotyping method is widespread for testing expectant parents in pregnancy planning.

Nanophore ATP Mass Parallel DNA Sequencer

"Nanophore SPS" operates on domestic reagents compatible with Illumina reagents, which are considered the gold standard in DNA sequencing to date. Sintol was engaged in their synthesis. Optics for the device was created by the Institute of Analytical Instrumentation of the Russian Academy of Sciences. Experts of the institute were also responsible for the development of original software that allows obtaining high-quality data.

According to scientists, all the main aspects of the mass parallel sequencing method were developed by Soviet and Russian scientists. Therefore, the developers are not afraid of patent disputes with the global market giant NGS - Illumina. They argue that there is evidence that the basic details of the technology were released 10 or more years before the advent of Illumina.

By the end of June 2023, the developers are engaged in the registration procedure for Nanophore SPS and all related reagents as medical devices. In the future - closing the need for domestic medicine in sequencers for mass parallel sequencing, as well as export.[1]

Notes